Open AccessUrinary Placental Growth Factor for Prediction of Placental Adverse Outcomes in High-Risk Pregnancies
Author(s) -
Édouard Lecarpentier,
JeanChristophe Gris,
Éva Cochery-Nouvellon,
É. Mercier,
Houria Abbas,
Ravi Thadhani,
S. Ananth Karumanchi,
Bassam Haddad
Publication year - 2019
Publication title -
obstetrics and gynecology (new york. 1953. online)/obstetrics and gynecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.664
H-Index - 220
eISSN - 1873-233X
pISSN - 0029-7844
DOI - 10.1097/aog.0000000000003547
Subject(s) - medicine , preeclampsia , gestation , aspirin , pregnancy , placental abruption , placental growth factor , urinary system , creatinine , interquartile range , obstetrics , gestational age , genetics , biology
To evaluate whether urinary levels of placental growth factor (PlGF) during pregnancy are associated with the subsequent development of composite adverse outcomes (preeclampsia, fetal growth restriction, placental abruption, perinatal death, maternal death) occurring at less than 34 weeks of gestation.